M&A - Medera Inc.
Form Type: 425
Filing Date: 2025-02-11
Corporate Action: Merger
Type: New
Accession Number: 000121390025011892
Filing Summary: Medera Inc. and Keen Vision Acquisition Corporation (KVAC) have entered into a Merger Agreement dated September 3, 2024, to execute a business combination in two steps. First, KVAC will merge with its wholly-owned subsidiary, KVAC (Cayman) Limited, resulting in the formation of a publicly traded entity named PubCo. Subsequently, KVAC MS (Cayman) Limited, another subsidiary of NewCo, will merge with Medera, making Medera a wholly-owned subsidiary of PubCo. The company outlines its strategic focus on gene therapies targeting challenging diseases, including heart failure and Duchenne Muscular Dystrophy, signaling a strong pipeline with potential pivotal trials and regulatory submissions expected between 2025 and 2028. Key management and clinical efforts are highlighted, with notable advancements in cardiac gene therapies and a robust patent portfolio for therapeutic assets. The presentation also notes forward-looking statements regarding the financial outlook and planned expansions in international markets.
Additional details:
Subject Company: Medera Inc.
Merger Agreement Date: 2024-09-03
Business Combination Steps: ["Reincorporation Merger of KVAC with KVAC (Cayman) Limited","Acquisition Merger of KVAC MS (Cayman) Limited with Medera"]
Key Management: ["Ronald Li, PhD - CEO","Roger Hajjar, MD - President, CMO","Allen Ma, CFA - CFO","Kevin Costa, PhD - Co-founder","Suresh Pullela, PhD - Chief Quality Officer","Jeff Rudy, MS - COO"]
Clinical Trials: [{"therapy":"SRD - 001","target":"HFrEF","phase":"Phase 1\/2a","next_steps":"Phase 2b to begin in Q2 2025"},{"therapy":"SRD - 002","target":"HFpEF","phase":"Phase 1\/2a","next_steps":"Phase 2b\/3 to begin in H2 2025"},{"therapy":"SRD - 003","target":"DMD-CM","phase":"Phase 1\/2a","next_steps":"Phase 2b\/3 to begin in H2 2026"}]
Patent Expiry Range: 2027 to 2042
Comments
No comments yet. Be the first to comment!